To evaluate prevalence and clinical features of immune-related adverse events (irAEs) to immune checkpoint inhibitors (ICIs) in accordance with the gender of treated cancer patients.
Triggianese, P., Novelli, L., Galdiero, M.r., Chimenti, M.s., Conigliaro, P., Perricone, R., et al. (2020). Immune checkpoint inhibitors-induced autoimmunity: The impact of gender. AUTOIMMUNITY REVIEWS, 19(8), 102590 [10.1016/j.autrev.2020.102590].
Immune checkpoint inhibitors-induced autoimmunity: The impact of gender
Triggianese, Paola;Chimenti, Maria Sole;Conigliaro, Paola;Perricone, Roberto;
2020-08-01
Abstract
To evaluate prevalence and clinical features of immune-related adverse events (irAEs) to immune checkpoint inhibitors (ICIs) in accordance with the gender of treated cancer patients.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
